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It has been reported that sigma receptors are highly expressed in
a variety of human tumors. In this study, we selected (+)-2-[4-(4-
iodophenyl)piperidino] cyclohexanol [(+)-pIV] as a sigma receptor
ligand and evaluated the potential of radioiodinated (+)-pIV for
tumor imaging and therapy. (+)-[125/131I]pIV was prepared by an
iododestannylation reaction under no-carrier-added conditions with
radiochemical purity over 99% after HPLC purification. Biodistribution
experiments were performed by the intravenous injection of
(+)-[125I]pIV into mice bearing human prostate tumors (DU-145).
Blocking studies were performed by intravenous injection of (+)-
[125I]pIV mixed with an excess amount of unlabeled sigma ligand
into DU-145 tumor-bearing mice. For therapeutic study, (+)-[131I]pIV
was injected at a dose of 7.4 MBq followed by measurement of the
tumor size. In biodistribution experiments, (+)-[125I]pIV showed high
uptake and long residence in the tumor. High tumor to blood and
muscle ratios were achieved because the radioactivity levels of blood
and muscle were low. However, the accumulations of radioactivity
in non-target tissues, such as liver and kidney, were high. The
radioactivity in the non-target tissues slowly decreased over time.
Co-injection of (+)-[125I]pIV with an excess amount of unlabeled
sigma ligand resulted in a significant decrease in the tumor/blood
ratio, indicating sigma receptor-mediated tumor uptake. In therapeutic
study, tumor growth in mice treated with (+)-[131I]pIV was significantly
inhibited compared to that of an untreated group. These results
indicate that radioiodinated (+)-pIV has a high potential for sigma
receptor imaging in tumor and radionuclide receptor therapy. (Cancer
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I t has been reported that there are at least two subtypes ofsigma receptors, designated sigma-1 and sigma-2.(1) Whereas
the sigma-1 receptor subtype has been cloned from various
tissues and species,(2,3) the sigma-2 receptor subtype has not yet
been cloned. The functions of sigma receptors have not yet been
clearly defined. In the central nervous system, they have been
shown to be involved in the regulation of neurotransmitter
release, modulation of neurotransmitter receptor function, learning
and memory processes, and regulation of movement and
posture.(4) Although they are expressed in peripheral tissues such
as liver, kidney, and endocrine organs, their function in these
tissues has been much less understood. At the same time, it has
been reported that both sigma receptor subtypes are highly
expressed in a variety of human tumors such as prostate cancer,
breast cancer, malignant melanoma, glioma, neuroblastoma, and
non-small-cell lung carcinoma.(5,6) The high expression of sigma
receptors in tumors suggests that they are appropriate targets for
developing tumor-imaging agents. Furthermore, sigma receptors
should be potential biomarkers of tumor proliferation because
they are highly expressed in rapidly proliferating cells and are
down-regulated when cells become quiescent.(7–9) For the time
being, radiolabeled sigma ligands should be useful for monitoring
the effects of chemotherapy at an early stage when morphologic
changes are not observed.(10)
Previously, we have developed several vesamicol analogs
with iodine into the 4-phenylpiperidine moiety as sigma receptor
imaging agents for investigating the central nervous system,
and determined the binding affinities for the sigma receptors of
the vesamicol analogs.(11,12) In these vesamicol analogs, the (+)-
enantiomer of 2-[4-(4-iodophenyl)piperidino] cyclohexanol
[(+)-pIV] (Fig. 1) showed the highest affinities for the recep-
tors.(12) The inhibition constant (Ki) of (+)-pIV to sigma-1 and
sigma-2 was 1.3 nM and 20.4 nM, respectively. The values
mean that (+)-pIV has more than 10-times greater affinity for
sigma-1 than that of (+)-pentazocine (Ki = 19.9 nM), which is
known as a sigma-1 ligand, and the sigma-2 affinity of (+)-pIV is
equivalent to that of 1,3-di(2-toyl)guanidine (DTG) (Ki = 22.5 nM),
which is known as a non-selective sigma ligand.
In this study, to evaluate the potential of radioiodinated
(+)-pIV for tumor imaging and receptor radionuclide therapy,
we selected human DU-145 prostate cancer cells known to over-
express sigma-1 and sigma-2 receptors(13) for preparation of
tumor-bearing mice, and a biodistribution study, metabolite
analysis, and therapeutic experiments were performed.
Materials and Methods
Chemicals. [125I]Sodium iodide and [131I]sodium iodide were
purchased from Perkin Elmer (Waltham, MA, USA). TLC
analyses were performed with silica plates (Art 5553; Merck,
Darmstadt, Germany). (3,4-Dimethoxyphenethyl)-4-(3-
phenylpropyl)piperazine (SA4503) was kindly supplied by M’s
Science (Kobe, Japan). Other reagents were of reagent grade
and used as received.
Preparation of (+)-enantiomer of (+)-pIV. The (+)-enantiomer of
p-iodovesamicol [(+)-pIV] was prepared using a method described
previously.(14,15) Briefly, (+)-pIV was synthesized from the (+)-
enantiomer of vesamicol, which was provided from racemic
vesamicol by recrystallizing the diastereoisomeric salts using
Fig. 1. Chemical structure of (+)-2-[4-(4-iodophenyl)piperidino] cyclo-
hexanol [(+)-pIV].
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(–)-di-p-toluoyl-D-tartaric acid monohydrate, via a three-step
reaction of nitration, amination, and iodination.
Preparation of (+)-[125I]pIV and (+)-[131I]pIV. (+)-[125I]pIV and
(+)-[131I]pIV were prepared according to procedures described
preciously with a slight modification.(16) Briefly, [125I]sodium
iodide solution (18.5 MBq/5 μL) or [131I]sodium iodide solution
(74 MBq/3 μL) was added to 5 μL of 3 M formic acid. (+)-2-
[4-(4-Tributylstannyl)phenylpiperidino]cyclohexanol [(+)-p-
tributylstannylvesamicol] (3 μg), synthesized as described
previously,(17) in ethanol (3 μL) and 5 μL of 3% H2O2 was added
and the reaction mixture was gently shaken. After 20 min of
standing at room temperature, the reaction mixture was quenched
with 3 μL of 10 M sodium hydroxide solution and then purified
by reversed phase (RP)-HPLC performed with a Cosmosil
5C18-AR 300 column (4.6 × 150 mm; Nacalai Tesque, Kyoto,
Japan) at a flow rate of 1 mL/min with a mixture of acetonitrile,
water, and ethanolamine (75:25:0.05) as a mobile phase.
Biodistribution of (+)-[125I]pIV in tumor-bearing mice. Experiments
with animals were conducted in accordance with the Guidelines
for the Care and Use of Laboratory Animals of Kanazawa
University. The animals were housed with free access to food
and water at 23°C with a 12-h alternating light/dark schedule.
DU-145 cells were obtained from ATCC (Manassas, VA, USA)
and grown in cell culture dishes in RPMI-1640 medium with
phenol red, 10% heat-inactivated fetal calf serum, 100 μg/mL
glutamine, 100 units/mL penicillin, and 100 μg/mL streptomycin.
The cells were cultured in a humidified atmosphere of 95% air
and 5% carbon dioxide at 37°C. They were then released from
the dishes by treatment with 0.05% trypsin/EDTA. Next, the
mice to be inoculated were anesthetized with pentobarbital. To
produce tumors, approximately 5 × 106 of the prepared cells
were injected subcutaneously into the right dorsum of 4-week-
old-male BALB/c nude mice (15–19 g; Japan SLC, Hamamatsu,
Japan). Biodistribution experiments were performed at approxi-
mately 14–21 days postinoculation, i.e. when tumors reached a
palpable size. Groups of four or five mice were intravenously
administered 100 μL of (+)-[125I]pIV (37 kBq). At 1, 24, and
48 h postinjection, the mice were sacrificed. Tissues of interest
were removed and weighed, and radioactivity counts were
determined with an auto well gamma counter (ARC-380; Aloka,
Tokyo, Japan) and corrected for background radiation.
Blocking studies. For blocking studies, the above-mentioned
DU-145 tumor-bearing mice were intravenously administered
100 μL of (+)-[125I]pIV (37 kBq) mixed with an excess of each
unlabeled sigma ligand, haloperidol (10 μmol/kg), SA4503
(10 μmol/kg), or (+)-pIV (10 μmol/kg), respectively. At 1 h
postinjection, the mice were sacrificed and biodistribution
experiments were conducted as described above.
Metabolite analysis in blood, tumor, and other tissues. For meta-
bolite analysis, the above-mentioned DU-145 tumor-bearing
mice were intravenously administered 100 μL of (+)-[125I]pIV
(370 kBq). At 1 and 24 h postinjection, the mice were sacrificed.
Blood was collected by heart puncture using a heparinized
syringe, and tissues of interest were removed. The blood was
centrifuged at 7000 g for 10 min at 4°C. After collecting the
plasma, an equivalent volume of acetonitrile-water (1:1) was
added to the plasma. The mixture was centrifuged at 7000 g for
10 min at 4°C. The tissues of interest (0.2–0.5 g) were homo-
genized in 1 mL of acetonitrile-water (1:1). Each homogenized
sample was centrifuged at 7000 g for 10 min at 4°C. The
supernatants were analyzed by TLC with ethyl acetate, hexane,
and ethanolamine (3:7:0.1) as a developing solvent.
Determination of the partition coefficient. The partition co-
efficient of (+)-[125I]pIV was measured as described previously
with a slight modification.(18,19) Namely, (+)-[125I]pIV was mixed
with 3 mL each of 1-octanol and phosphate buffer (0.02 M,
pH 7.4) in a test tube. The mixture was vortexed for 10 min.
After vortex, the mixture was centrifuged at 1000 g for 5 min.
2.5 mL of 1-octanol was removed and added to 2.5 mL of new
phosphate buffer (0.02 M, pH 7.4). After repeating the same
procedure twice, 100 μL and 1 mL of 1-octanol and phosphate
buffer were taken and their radioactivity and weight were
measured. The partition coefficient was determined by calculating
the ratio of cpm/mL in 1-octanol to that in the buffer, and
expressed as a common logarithm (log P).
Therapy. The mice were randomly distributed in the experi-
mental groups. When the tumors had reached a palpable size,
(+)-[131I]pIV was injected intravenously at a dose of 7.4 MBq. A
group of untreated mice served as a control group. After
injection, tumor size was measured with a slide caliper in two
dimensions, and mouse weights were measured 2–3 times per
week. Individual tumor volumes (V) were calculated by the
formula V = [length × (width)2]/2 and compared to the values on
the day of treatment (relative tumor volume).
Statistical evaluation. An unpaired Student’s t-test was used
for the therapeutic experiments. One-way anova followed by
Dunnett’s post-hoc test compared to the control group was used
for experiments in the blocking study. Results were considered
statistically significant at P < 0.05.
Results
Preparation of (+)-[125I]pIV. (+)-[125I]pIV and (+)-[131I]pIV were
prepared by the iododestannylation reaction under no-carrier-
added conditions with high radiochemical yield (87% and 83%,
respectively). After purification by RP-HPLC, (+)-[125I]pIV and
(+)-[131I]pIV showed radiochemical purities of over 99%.
Biodistribution experiments of (+)-[125I]pIV in tumor-bearing
mice. Table 1 lists the biodistribution of (+)-[125I]pIV in DU-145
tumor-bearing mice. (+)-[125I]pIV showed high uptake and long
retention in the tumors. Since the radioactivity levels in blood
and muscle were low, high tumor to blood and muscle ratios
were achieved. However, the accumulation of radioactivity in
abdominal organs such as liver and kidney was high. The
clearance of radioactivity in these organs was faster than that in
the tumor. At the same time, the accumulation of (+)-[125I]pIV
in the stomach was low, indicating that deiodination was not
observed in vivo.
Blocking studies. The effects of some sigma ligands on tumor
uptake of (+)-[125I]pIV at 1 h postinjection are shown as %
injected dose per gram in tumor in Figure 2. Co-injection of
an excess amount of haloperidol, SA4503, or (+)-pIV resulted
in a significant decrease in tumor uptake after injection of
(+)-[125I]pIV.
Fig. 2. Comparison of tumor uptake (mean ± SD) of (+)-[125I]pIV at 1 h
postinjection under no-carrier-added conditions and under co-injection of
haloperidol, SA4503, or (+)-2-[4-(4-iodophenyl)piperidino] cyclohexanol
[(+)-pIV]. Significance was determined using one-way ANOVA followed by
Dunnett’s post-hoc test (*P < 0.05, **P < 0.01 vs. control).
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Metabolite analysis in blood, tumor, and other tissues. Table 2
lists the results of the metabolite analyses after intravenous
injection of (+)-[125I]pIV in DU-145 tumor-bearing mice. At 1 h
postinjection, large proportions of radioactivity existed as an
intact form in almost all tissues except blood. In contrast, at 24 h
postinjection, the proportions of the intact form in all tissues
were much lower than those at 1 h postinjection. At 24 h
postinjection, radioactivity in the tumor showed a relatively
large proportion of the intact form (40.7%) compared with
those in other tissues. In blood, almost no intact (+)-[125I]pIV
was observed at 1 and 24 h postinjection (3.7% and 1.4%,
respectively).
Determination of the partition coefficient. The log P-value of
(+)-[125I]pIV was 2.08 ± 0.02 (mean ± SD for four samples).
Therapy. The volume of the tumors as a function of time is
shown in Figure 3. As can be seen, tumor growth in the mice
treated with (+)-[131I]pIV was significantly inhibited compared
to that of the untreated group. Weight could be used as a marker
for the general health of the mice (Fig. 4). The mice treated with
(+)-[131I]pIV lost weight, which was probably caused by
treatment-related toxicity, but the weight loss was less than 10%
of their starting body weight.
Table 1. Biodistribution of radioactivity after intravenous injection of
(+)-[125I]pIV in tumor-bearing mice
Tissue
Time after injection
1 h 24 h 48 h
Blood 0.24 0.71 0.37
(0.03) (0.05) (0.06)
Tumor 6.27 8.78 6.04
(1.00) (0.41) (1.19)
Liver 16.91 15.23 5.24
(0.79) (0.62) (0.41)
Kidney 16.24 9.38 4.21
(2.52) (0.60) (0.28)
Intestine 6.44 4.89 1.50
(1.10) (0.16) (0.19)
Spleen 13.62 4.04 1.75
(2.73) (0.53) (0.25)
Lung 15.62 3.83 1.81
(5.87) (0.44) (0.62)
Heart 8.21 1.62 0.65
(1.85) (0.21) (0.07)
Stomach† 0.66 0.59 0.27
(0.09) (0.05) (0.05)
Brain 7.65 2.89 1.08
(2.15) (0.10) (0.09)
Muscle 2.41 0.64 0.30
(0.77) (0.17) (0.09)
T/B ratio 26.20 12.39 16.48
(4.23) (0.98) (2.16)
T/M ratio 2.72 14.30 20.54
(0.55) (2.76) (2.02)
Data are expressed as % injected dose per gram tissue. Each value 
represents the mean (SD) for four or five animals.
†Data are expressed as % injected dose.
T/B ratio, tumor : blood ratio; T/M ratio, tumor : muscle ratio.
Table 2. Analysis of metabolites after intravenous injection of (+)-
[125I]pIV in tumor-bearing mice
Tissue
Time after injection













Data are expressed as % of intact (+)-[125I]pIV. Each value represents the 
mean (SD) for three samples.
Fig. 3. Curves depicting inhibition of growth of DU-145 on therapy with
(+)-[131I]pIV (closed circles) compared with no treatment (open circles).
Data are expressed as tumor volume relative to that on the day of
treatment (mean ± SEM for four mice). Significance was determined
using the Student’s t-test (*P < 0.05, **P < 0.01 vs. untreated group).
Fig. 4. Body weight of DU-145 tumor-bearing mice treated with (+)-
[131I]pIV (closed circles) or with no treatment (open circles). Data are
expressed as relative value to initial body weight (mean ± SEM for four
mice).
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Discussion
In the case of the differential diagnosis of tumors, information
obtained from Single photon emission computed tomography
(SPECT) or PET imaging should be more important than that
from other imaging modalities such as CT, MRI, or ultrasound.
That is to say, among those imaging modalities, nuclear medicine
modality is most advantageous for detecting functional changes
such as changes of receptor density, metabolism, and so on. It
has been reported that the density of sigma receptors affects the
condition of tumors.(7,20) Therefore, nuclear imaging agents for
sigma receptors could be useful in the differential diagnosis of
tumors.(9) In this study, we first examined the potential of
radioiodine-labeled (+)-pIV, which has a very high affinity for
sigma receptors, as a tumor-imaging agent.
In the biodistribution experiments in the tumor-bearing mice,
(+)-[125I]pIV showed a high uptake of radioactivity in the DU-145
tumor as we expected. Tu et al. described that not only receptor
affinity but also optimal lipophilicity is important in the design
of receptor-based tumor-imaging agents.(21) The measured
partition coefficient (log P) for (+)-[125I]pIV was 2.08. The value
was much less than what we expected because the calculated log
P-value for pIV was 4.45 using CS ChemDraw Ultra software
(Cambridge Soft, Cambridge, MA, USA). A slight contamination
or the presence of hydrophilic impurities could underestimate
the log P-value. Then, it might be difficult to accurately determine
the log P-value for a high lipophilicity radioactive compound
via the shake-flask method. Although it is not clear whether the
lipophilicity of (+)-pIV is optimal for tumor uptake, part of the
high uptake in tumors might be derived from the appropriate
lipophilicity of (+)-[125I]pIV. Additionally, since (+)-[125I]pIV
showed low radioactivity in blood and muscle, high tumor to
blood and muscle ratios were achieved (Table 1). In order to
determine in vivo binding of (+)-[125I]pIV to sigma receptors,
(+)-[125I]pIV was co-injected with excess amounts of some types
of sigma ligands. The co-injection significantly decreased tumor
uptake of radioactivity (Fig. 2), which indicates the receptor
specificity of (+)-[125I]pIV uptake in DU-145 tumors in vivo.
These results indicate that (+)-pIV labeled with I-123 and I-124
instead of I-125 as a radionuclide could be useful as sigma
receptor-imaging agents in tumors for SPECT and PET, respec-
tively. Meanwhile, from our previous in vitro experiments,(12) we
assume that (+)-[125I]pIV prefers sigma-1, but could bind to not
only sigma-1 but also sigma-2. Sigma-1 and sigma-2 receptors
are highly expressed in DU-145 cells.(13) In this study, SA4503
inhibited tumor uptake of (+)-[125I]pIV more strongly than with
haloperidol. SA4503 binds mainly to sigma-1, and haloperidol
is a non-selective sigma ligand.(22) Therefore, the results from
the in vivo experiments in this study suggest that (+)-[125I]pIV
binds to sigma-1 receptors, but it is not clear whether (+)-[125I]pIV
also binds to sigma-2 receptors.
The problem of the tracer was high accumulations of radi-
oactivity in non-target tissues, such as liver and kidney. As
described in the introduction section, since sigma receptors are
expressed in not only tumor but also non-target tissues such as
in the liver and kidney, some parts of the accumulation of the
radioactivity in non-target tissues should be sigma receptor–
specific. It may be difficult to avoid some uptakes in non-target
tissues for labeled sigma ligands. Tu et al. mentioned that
sigma-1-selective or sigma-1/sigma-2-non-selective compounds
might not be ideal candidates for imaging tumors because many
kinds of tumors possess a higher density of sigma-2 receptors
than the surrounding normal tissue. On the other hand, the density
of sigma-1 receptors in tumor cells is generally less than that
present in normal tissues.(21) Although it was reported that rat
liver and kidney contain high densities of sigma-1 and sigma-2
receptors with sigma-2 sites comprising 75–80% of the total
sigma receptors population,(23) Mach et al. performed biodistri-
bution experiments with a 18F-labeled compound possessing
a high affinity for both sigma-1 and sigma-2 receptors with
co-injection of the unlabeled sigma-1 selective ligand and showed
that the blocking of sigma-1 receptors reduced the accumula-
tion of radioactivity in non-target tissues except liver.(24) Their
studies indicate that labeled specific sigma-2 ligands could
show less accumulation in non-target tissues compared with
sigma-1-specific or non-selective ligands. At the same time,
lipophilicity might affect not only tumor uptake but also
non-target tissue uptake and higher lipophilicity might lead to
high non-specific uptake in both target and non-target tissues.(25,26)
Some parts of the accumulation of (+)-[125I]pIV in non-target
tissues, especially in liver, should be derived from its lipophilicity.
Although the radioactivity in the non-target tissues gradually
decreased compared to that in tumor, the clearance of the
radioactivity in the non-target tissues was not fast. Conse-
quently, it most likely interferes with the acquisition of clear
images at early times after injection of radioiodine-labeled
(+)-pIV.
In the metabolite studies, the clearance of the intact (+)-
[125I]pIV in tumors was slower than that in any other organ
(Table 2). When we calculated (% injected dose per gram)
× (ratio of intact (+)-[125I]pIV) at 24 h postinjection of (+)-
[125I]pIV, the values for blood, tumor, liver, kidney, lung, and
brain were 0.01, 3.57, 1.58, 0.82, 0.42, and 0.66, respectively.
Much more intact (+)-[125I]pIV remained in tumors compared
with that in other organs. Whether these results were caused by
differences of metabolic rate is not clear from our data. Even if
more intact (+)-[125I]pIV in tumors is caused by a slow meta-
bolic rate, further studies would be needed to elucidate the
causes. However, more intact (+)-[125I]pIV should affect the
more prolonged residence in tumors than that in other organs.
Actually, previous studies have reported that the clearance of the
sigma ligands from the brain was faster than those from
tumors.(13,24,27,28) The long residence of radiotracer in tumors is
convenient for internal radiotherapy. Accordingly, we supposed
that radioiodinated (+)-pIV could also be used as an internal
radionuclide therapy by using I-131, which emits middle energy
of beta particles for therapy, instead of I-125. We examined the
potential of (+)-[131I]pIV as a therapeutic agent. As a result, a
single treatment with (+)-[131I]pIV (7.4 MBq/mice) achieved
significant inhibition of tumor growth in tumor-bearing mice
compared with a control group (Fig. 3). As far as we know, this
was the first trial to use a radiolabeled sigma ligand for receptor
radionuclide therapy. Although the data are insufficient, these
results indicate that (+)-[131I]pIV has potential as an agent for
radionuclide receptor therapy.
In conclusion, radioiodinated (+)-pIV has a high potential
for sigma receptor imaging in tumor and radionuclide receptor
therapy because of its high tumor uptake via sigma receptor in
an animal model. However, further studies are needed in order
to reduce the radioactivity levels in non-target tissues.
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